ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

JAK2

Janus kinase 2 · also JTK10 · SH2 domain containing

14 programs in company-led studies act on JAK2, from 13 companies: 6 in phase 3, 5 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
upadacitinibruleAbbVieinhibitorphase 46424 runningJAK1, JAK3, TYK2ChEMBL
ruxolitinibruleIncyteinhibitorphase 49518 runningJAK1, JAK3, TYK2ChEMBL
baricitinibruleEli Lillyinhibitorphase 4598 runningJAK1ChEMBL
tofacitinibrulePfizerinhibitorphase 4943 runningJAK1, JAK3, TYK2ChEMBL
filgotinib maleateruleEisaiinhibitorphase 421 runningJAK1, JAK3, TYK2ChEMBL
jaktinibruleSuzhou Zelgen Biopharmaceuticalsinhibitorphase 3318 runningFLT3, JAK1, JAK3the studies' text
filgotinibruleLakefront Biotherapeutics NVinhibitorphase 3464 runningJAK1, JAK3, TYK2ChEMBL
momelotinibruleGlaxoSmithKlineinhibitorphase 3174 runningACVR1, JAK1NCIt
flonoltinibruleChengdu Zenitar Biomedical Technologyinhibitorphase 374 runningCDK6, FLT3the studies' text
pacritinibruleSwedish Orphan Biovitruminhibitorphase 3183 runningACVR1, FLT3, IRAK1NCIt
delgocitinibruleLEO Pharmainhibitorphase 3212 runningJAK1, JAK3, TYK2ChEMBL
JAK2 Inhibitor TQ05105Sino Biopharmaceuticalinhibitorphase 2167 running–a judged reading
flonoltinib maleateruleChengdu Zenitar Biomedical Technologyinhibitorphase 221 runningFLT3NCIt
JAK2V617F Inhibitor PRT12396rulePrelude Therapeuticsinhibitorphase 111 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.